Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Point Therapeutics' lead product candidate, PT-100, has demonstrated tumor growth suppression of several different human tumor types in preclinical studies, as well as boosting the anti-tumor activity of docetaxel in lung cancer.
Subscribe to our email newsletter
In previously published studies, PT-100 (talabostat) was shown to elicit anti-tumor T-cell responses in mice with fully functioning immune systems. The recently announced results have advanced this work by demonstrating that talabostat can induce inhibition of tumor growth, independent of T-cell activity, by 60 to 90% in xenograft models of B-cell lymphoma, melanoma, osteosarcoma, head-and-neck cancer, pancreatic cancer and non-small cell lung cancer (NSCLC).
In the NSCLC immunodeficient mouse model, further results demonstrated a greatly improved anti-tumor effect when talabostat was combined with docetaxel (Sanofi-Aventis’ Taxotere). The anti-tumor effect of docetaxel and PT-100 was significantly greater than that of either agent alone. On day 51, single agent treatment with either PT-100 or docetaxel was observed to inhibit tumor growth by 60 to 70%, whereas combination treatment resulted in 90% inhibition.
These results, combined with previously published studies, indicate that talabostat possesses both the potential to enhance the activity of commonly used chemotherapy regimens and the potential to treat human cancers refractory to T-cell immune attack.